Triple-negative breast cancer (TNBC) is considered one of the most aggressive forms of breast cancer with poor survival rates compared to other breast cancer subtypes. TNBC is characterized by the absence of the estrogen receptor alpha, progesterone receptor, and the human epidermal growth factor receptor 2, limiting those viable treatment options available to patients with other breast cancer subtypes. Furthermore, due to the particularly high heterogeneity of TNBC, conventional treatments such as chemotherapy are not universally effective, leading to drug resistance and intolerable side effects. Thus, there is a pressing need to discover new therapies beneficial to TNBC patients. This review highlights current findings regarding the roles of three steroid hormone receptors, estrogen receptor beta, the androgen receptor, and the glucocorticoid receptor, in the progression of TNBC. In addition, we discussed several ongoing and completed clinical trials targeting these hormone receptors in TNBC patients.
三阴性乳腺癌（TNBC）被认为是乳腺癌中最具侵袭性的亚型之一，与其他乳腺癌亚型相比生存率较低。其典型特征为缺乏雌激素受体α、孕激素受体和人表皮生长因子受体2的表达，这限制了患者使用其他乳腺癌亚型有效的治疗方案。此外，由于三阴性乳腺癌具有极高的异质性，化疗等传统治疗方法并非普遍有效，常导致耐药性和难以耐受的副作用。因此，迫切需要探索对三阴性乳腺癌患者有益的新疗法。本综述重点阐述了三种类固醇激素受体——雌激素受体β、雄激素受体和糖皮质激素受体在三阴性乳腺癌进展中的作用机制研究现状，并讨论了针对这些激素受体在三阴性乳腺癌患者中开展的多项正在进行及已完成的临床试验。
The Potential of Hormonal Therapies for Treatment of Triple-Negative Breast Cancer
肿瘤(癌症)患者之家